Zobrazeno 1 - 10
of 28
pro vyhledávání: '"C H van Dyck"'
Autor:
Nicholas Jackson, Enchi Liu, C H van Dyck, Nzeera Ketter, B T Wyman, M Slomkowski, Kenneth Marek, Yahong Peng, Kevin Booth, J M Ryan, G Le Prince Leterme, Carl H. Sadowsky
Publikováno v:
The journal of prevention of Alzheimer's disease. 3(2)
BACKGROUNDd: ACC-001 is an investigational therapeutic vaccine designed to elicit antibodies against the N-terminal peptide 1-7 of the amyloid-beta peptide, believed to be important in the pathogenesis of Alzheimer’s disease. OBJECTIVES: To evaluat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c4d60467ed6bbeaba9bc8f130d7786d
https://pubmed.ncbi.nlm.nih.gov/29210443
https://pubmed.ncbi.nlm.nih.gov/29210443
Autor:
Reisa A. Sperling, Ron Keren, Gerald Crans, C H van Dyck, Susan Abushakra, Aleksandra Pastrak, G. Quinn, Jesse M. Cedarbaum, Menghis Bairu, Chito Hernandez, Earvin Liang, Pierre N. Tariot, Sid Gilman, Anton P. Porsteinsson, Stephen Salloway, Douglas L. Arnold
Publikováno v:
Neurology. 77:1253-1262
Objective: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD). Methods: A total
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9f00614a54de9d7fd89bfcec94ecba3
https://doi.org/10.1212/wnl.0b013e3182309fa5
https://doi.org/10.1212/wnl.0b013e3182309fa5
Autor:
Douglas Galasko, Mary Sano, R. G. Thomas, C H van Dyck, Paul S. Aisen, Karen L. Bell, James E. Galvin
Publikováno v:
Neurology. 77:556-563
Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf34c7b3e032ce0b1b3a6f04f94ae7a0
https://doi.org/10.1212/wnl.0b013e318228bf11
https://doi.org/10.1212/wnl.0b013e318228bf11
Autor:
Michael Grundman, Nick C. Fox, K.M. Gregg, E. Liu, Dale Schenk, Murray A. Raskind, Marwan N. Sabbagh, Stephen Salloway, Ruth A. Mulnard, Sid Gilman, Kaj Blennow, I. Lieberburg, C H van Dyck, Ronald Black, Rachelle S. Doody, Reisa A. Sperling, Jerome Barakos, Lawrence S. Honig
Publikováno v:
Salloway, S, Sperling, R, Gilman, S, Fox, N C I, Blennow, K, Raskind, M, Sabbagh, M, Honig, L S, Doody, R, van Dyck, C H, Mulnard, R, Barakos, J, Gregg, K M, Liu, E, Lieberburg, I, Schenk, D, Black, R & Grundman, M 2009, ' A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease ', Neurology, vol. 73, no. 24, pp. 2061-2070 . https://doi.org/10.1212/WNL.0b013e3181c67808
Neurology, 73(24), 2061-2070. Lippincott Williams and Wilkins
Neurology, 73(24), 2061-2070. Lippincott Williams and Wilkins
Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.The study enrolled 234 patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0971ceb476daa37b40ef115e1a66191f
https://doi.org/10.1212/wnl.0b013e3181c67808
https://doi.org/10.1212/wnl.0b013e3181c67808
Publikováno v:
Neurology. 71:1702-1708
Background: In animals, insulin-like growth factor-1 (IGF-1) increases clearance of β-amyloid, a pathologic hallmark of Alzheimer disease (AD), from the CNS. Serum IGF-1 level decreases with age, and shows a further decrease in AD. We examined wheth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9244bf817ca87d6bf500efc9f53fa06c
https://doi.org/10.1212/01.wnl.0000335163.88054.e7
https://doi.org/10.1212/01.wnl.0000335163.88054.e7
Autor:
H R Pearsall, Patrick G. O'Connor, Marc I. Rosen, Scott W. Woods, C H Lin, Thomas J. McMahon, C H van Dyck, Stephanie S. O'Malley, Thomas R. Kosten
Publikováno v:
The Journal of Neuropsychiatry and Clinical Neurosciences. 9:29-36
Other investigators have reported clinical improvement from psychostimulant drugs in patients with HIV-1-related cognitive impairment. However, no previous research has substantiated this claim by using a controlled study design. We examined the effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f565023b37e7295d5b181591d60443
https://doi.org/10.1176/jnp.9.1.29
https://doi.org/10.1176/jnp.9.1.29
Autor:
John Seibyl, C H van Dyck, John H. Krystal, R. M. Baldwin, Marc Laruelle, Roberto Gil, Robert B. Innis, Cyril D'Souza, Anissa Abi-Dargham, W Rosenblatt, Elinore McCance, Dennis S. Charney, Christine L Fingado, Joseph Erdos, Sami S. Zoghbi
Publikováno v:
Proceedings of the National Academy of Sciences. 93:9235-9240
The dopamine hypothesis of schizophrenia proposes that hyperactivity of dopaminergic transmission is associated with this illness, but direct observation of abnormalities of dopamine function in schizophrenia has remained elusive. We used a newly dev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dc496e579e23144844587475c15be53
https://doi.org/10.1073/pnas.93.17.9235
https://doi.org/10.1073/pnas.93.17.9235
Autor:
S. Sawchak, C. H. van Dyck, Conn M. Harrington, John T. Davies, Marina Zvartau-Hind, Carl Chiang, C. Donovan, Michael Gold, Ann M. Saunders, B. Jeter, Michael C. Irizarry
Publikováno v:
Current Alzheimer research. 8(5)
Introduction: Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive therapy to ongoing acetylcholine esterase inhibitor (AChEI) treatment in AD (R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98f05e02aba41d14fd00750d921c28e8
https://pubmed.ncbi.nlm.nih.gov/21592048
https://pubmed.ncbi.nlm.nih.gov/21592048
Autor:
Shirley Eberly, C H van Dyck, M. Early, B. Fussell, Robert B. Innis, Kenneth Marek, John Seibyl, David Oakes
Publikováno v:
Neurology. 57(11)
Background: [ 123 I]β-CIT and SPECT imaging of the dopamine transporter is a sensitive biomarker of PD onset and severity. Objective: In this study, the authors examine the change in [ 123 I]β-CIT uptake in sequential SPECT scans to assess the rate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c07e607c87a44c2fb9c4bc9fe9e30a61
https://pubmed.ncbi.nlm.nih.gov/11739831
https://pubmed.ncbi.nlm.nih.gov/11739831
Autor:
J C, Soares, C H, van Dyck, P, Tan, S S, Zoghbi, P, Garg, R, Soufer, R M, Baldwin, M, Fujita, J K, Staley, X, Fu, L, Amici, J, Seibyl, R B, Innis
Publikováno v:
Psychiatry research. 106(2)
The test/retest reproducibility of brain measures of 5-HT2A receptors with positron emission tomography (PET) and [18F]deuteroaltanserin was examined in a group of eight healthy human subjects. PET measures of 5-HT2A receptors were obtained under an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ce1b9edfdfb33ae72dd5fbc882ac27d
https://pubmed.ncbi.nlm.nih.gov/11306248
https://pubmed.ncbi.nlm.nih.gov/11306248